Showing results (161-170 of 494) with videos related to
Sort By:
Pageof 50
Health Affairs (Project Hope)|May 2, 2022
Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved DrugsC Joseph Ross Daval, Ameet Sarpatwari, Aaron S KesselheimAnnals of Internal Medicine|July 30, 2014
Health policy basics: the Physician Payment Sunshine Act and the Open Payments programNeil M Kirschner, Lois Snyder Sulmasy, Aaron S KesselheimThe New England Journal of Medicine|November 13, 2014
High-cost generic drugs--implications for patients and policymakersJonathan D Alpern, William M Stauffer, Aaron S KesselheimJAMA Health Forum|August 17, 2022
Medicare Spending on Drugs With Accelerated Approval, 2015-2019Benjamin N Rome, William B Feldman, Aaron S KesselheimJournal of General Internal Medicine|November 12, 2025
Enhancing Formulary Accessibility: a Step Toward Better CareVictor C Agbafe, Aaron S Kesselheim, John S BarbieriHealth Affairs (Project Hope)|June 5, 2023
Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20Benjamin N Rome, Aayan N Patel, Aaron S KesselheimPediatrics|April 16, 2014
Postmarketing trials and pediatric device approvalsThomas J Hwang, Aaron S Kesselheim, Florence T BourgeoisJAMA Internal Medicine|September 8, 2020
US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer AcetateBenjamin N Rome, Frazer A Tessema, Aaron S KesselheimHealth Affairs (Project Hope)|June 4, 2014
Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in childrenIan Larkin, Desmond Ang, Jerry Avorn, et al.JAMA Network Open|January 15, 2026
Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare PatientsJacob S Riegler, Aaron S Kesselheim, Benjamin N RomePageof 50